MAAT INDEX

CLAIM #22656 · EMR (EMR) · 2024Q1 earnings call · Feb 7, 2024 · due Dec 31, 2024

We do expect a recovery in orders into the second half, of course, between comps and obviously some demand elements there.

Lal Karsanbhai · CEO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

oximately $400 million that represented almost a little over 90 projects that we won out of the funnel in the first quarter. The funnel grew despite that. And we continue to see activity, particularly in energy transition driven by the Middle East and Africa, in the sustainability area, life sciences, and of course, a tremendous amount of activity in metals and mining. So from an underlying Emerson perspective, the focus really is process and hybrid to continue to provide that underlying strength through the year. Now what we will see is a recovery in discrete in the second half, and that's what we've got baked in here. We are still in the lower single digits negative right now in our discrete markets. It's really demand-driven, as we've been talking about for the last couple of quarters. We do expect a recovery in orders into the second half, of course, between comps and obviously some demand elements there. As far as NI is concerned, it's very much on plan to what we expect in terms of orders. We do also believe that there's a second half positive return on the order activity. And we're starting to see early signs in markets, particularly like semiconductor, as you see these companies come out and report. So very much on plan on both ends and which gives us confidence in the underlying strength of the order activity, Andy. Andy Kaplowitz: Helpful. You obviously had a good quarter and raised the outlook. But maybe just on free cash flow, you didn't change your guidance despite the better quarter and outlook. Did you raise your acquisition-related costs? Is CapEx going up? Anything that you could talk about on that side or on the working capital side? Mike Baughman: Andy, it's Mike. I'll take

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2024Q1 earnings call.